Vitiligo as a systemic disease

Clinics in Dermatology

Volumn 32, Issue 3, 2014, Pages 430-434

  Lotti, Torello ^a   D'Erme, Angelo Massimiliano ^b  

^a UNIVERSITY OF ROME G MARCONI   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 6; MONOPHENOL MONOOXYGENASE; REACTIVE OXYGEN METABOLITE; THYROGLOBULIN ANTIBODY; THYROID ANTIBODY; TUMOR NECROSIS FACTOR;

ABDOMINAL OBESITY; ADDISON DISEASE; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; CARDIOVASCULAR RISK; CHORIORETINOPATHY; DERMATITIS HERPETIFORMIS; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENZYME INHIBITION; EPIDERMIS; GLUCOSE INTOLERANCE; HEMOLYTIC ANEMIA; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; HYPOPARATHYROIDISM; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LICHEN PLANUS; MELANOCYTE; METABOLIC SYNDROME X; METASTATIC MELANOMA; MORPHEA; NOTE; PERNICIOUS ANEMIA; POLYGLANDULAR SYNDROME TYPE 2; PRIORITY JOURNAL; PSORIASIS; RETINOPATHY; SYMPATHETIC OPHTHALMIA; THYROID FUNCTION; UVEA; VITILIGO; VOGT KOYANAGI SYNDROME; COMPLICATION; INFLAMMATION; PHENOTYPE; THYROID DISEASE;

HUMANS; INFLAMMATION; MELANOCYTES; PHENOTYPE; THYROID DISEASES; VITILIGO;

EID: 84899076108     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2013.11.011     Document Type: Note

References (41)

1. Taieb A., Alomar A., Böhm M., et al. The writing group of the Vitiligo European Task Force (VETF) in cooperation with the European Academy of Dermatology and Venereology (EADV) and the Union Européenne desecins Spécialistes (UEMS). Guidelines for the management of vitiligo: The European Dermatology Forum consensus. Br J Dermatol 2013 Jan, 168:5-19.
2. Lotti T., Hautmann G., Hercogovà J. Vitiligo: disease or symptom? From the confusion of the past to current doubts. Vitiligo. Problems and solutions 2004, 1-14. Basel: Marcel Dekker, Inc., New York, NY. T. Lotti, J. Hercogovà (Eds.).
3. Alikhan A., Felsten L.M., Daly M., Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol 2011, 65:473-491.
4. Vitiligo, A Monograph on the Basic and Clinical Science 2000, 89-96. Blackwell Science, Oxford. J. Nordlund, H. Seung-Kyung (Eds.).
5. Zelissen P.M., Bast E.J., Croughs R.J. Associated autoimmunity in Addison's disease. J Autoimmun 1995, 8:121-130.
6. Brostoff J. Autoantibodies in patients with vitiligo. Lancet 1969, 26:2177-2178.
7. Hercogová J., Schwartz R.A., Lotti T.M. Classification of vitiligo: a challenging endeavor. Dermatol Ther 2012, 25(Suppl. 1):S10-S16.
8. Hann S.K., Lee H.J. Segmental vitiligo: clinical findings in 208 patients. J Am Acad Dermatol 1996, 35(5 Pt 1):671-674.
9. Zhang Z., Xu S.X., Zhang F.Y., et al. The analysis of genetics and associated autoimmune diseases in Chinese vitiligo patients. Arch Dermatol Res 2009, 301:167-173.
10. Mazereeuw-Hautier J., Bezio S., Mahe E., et al. Segmental and nonsegmental childhood vitiligo has distinct clinical characteristics: a prospective observational study. J Am Acad Dermatol 2010, 62:945-949. Groupe de Recherche Clinique en Dermatologie Pédiatrique (GRCDP).
11. de Vijlder H.C., Westerhof W., Schreuder G.M., Claas F.H. Difference in pathogenesis between vitiligo vulgaris and halo nevi associated with vitiligo is supported by an HLA association study. Pigment Cell Res 2004, 17:270-274.
12. Hann S.K., Im S., Kim H.I., Kim H.S., Lee Y.J., Park Y.K. Increased incidence of antismooth muscle antibody in Korean vitiligo patients. J Dermatol 1993, 20:679-683.
13. Handa S., Kaur I. Vitiligo: clinical findings in 1436 patients. J Dermatol 1999, 26:653-657.
14. Pagovich O.E., Silverberg J.I., Freilich E., Silverberg N.B. Thyroid abnormalities in pediatric patients with vitiligo in New York City. Cutis 2008, 81:463-466.
15. Iacovelli P., Sinagra J.L., Vidolin A.P., et al. Relevance of thyroiditis and of other autoimmune diseases in children with vitiligo. Dermatology 2005, 210:26-30.
16. Kakourou T., Kanaka-Gantenbein C., Papadopoulou A., Kaloumenou E., Chrousos G.P. Increased prevalence of chronic autoimmune (Hashimoto's) thyroiditis in children and adolescents with vitiligo. J Am Acad Dermatol 2005, 53:220-223.
17. Frati R., Frati C., Sassano P.P., Antonaci A. Vitiligo, autoimmune thyroiditis: a rare thyroid cancer arising with bone metastates on maxillofacial area. J Exp Clin Cancer Res 1999, 18:85-87.
18. Barona M.I., Arrunátegui A., Falabella R., Alzate A. An epidemiologic case-control study in a population with vitiligo. J Am Acad Dermatol 1995, 33:621-625.
19. Hegedüs L., Heidenheim M., Gervil M., Hjalgrim H., Høier-Madsen M. High frequency of thyroid dysfunction in patients with vitiligo. Acta Derm Venereol 1994, 74:120-123.
20. Dittmar M., Kahaly G.J. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab 2003, 88:2983-2992.
21. Gould I.M., Gray R.S., Urbaniak S.J., Elton R.A., Duncan L.J. Vitiligo in diabetes mellitus. Br J Dermatol 1985 Aug, 113:153-155.
22. Moretti S., Arunachalam M., Colucci R., et al. Autoimmune markers in vitiligo patients appear correlated with obsession and phobia. J Eur Acad Dermatol Venereol 2012 Jul, 26:861-867.
23. Grunnet I., Howitz J., Reymann F., Schwartz M. Vitiligo and pernicious anemia. Arch Dermatol 1970, 101:82-85.
24. Bystryn J.C., Rigel D., Friedman R.J., Kopf A. Prognostic significante of hypopigmentation in malignant melanoma. Arch Dermatol 1987, 123:1053-1055.
25. Lerner A.B. Melanoma and vitiligo. Cancer Immunol Immunother 1997 Aug, 44:352-354.
26. Nordlund J.J., Kirkwood J.M., Forget B.M., Milton G., Albert D.M., Lerner A.B. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983 Nov, 9:689-696.
27. Lindelöf B., Hedblad M.A., Sigurgeirsson B. On the association between vitiligo and malignant melanoma. Acta Derm Venereol 1998 Nov, 78:483-484.
28. Pietrzak A., Bartosińska J., Hercogová J., Lotti T.M., Chodorowska G. Metabolic syndrome in vitiligo. Dermatol Ther 2012, 25(Suppl. 1):S41-S43.
29. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol 2012, 26(Suppl. 2):3-11.
30. Karadag A.S., Tutal E., Ertugrul D.T. Insulin resistance is increased in patients with vitiligo. Acta Derm Venereol 2011, 91:541-544.
31. Pietrzak A., Lecewicz-Torun' B., Urban J. Comparison of serum lipid in girls affected with vitiligo and control group. Ann Univ Mariae Curie Sklodowska Med 2000, 55:269-274.
32. Rodríguez-Martín M., de Paz N.M., Mehtani P., et al. Patients with vitiligo present fewer cardiovascular risk factors: results from a case-control study. J Eur Acad Dermatol Venereol 2013, 27:124-125.
33. Arunachalam M., Dragoni F., Colucci R., et al. Non-segmental vitiligo and psoriasis comorbidity-a case-control study in Italian patients. J Eur Acad Dermatol Venereol 2013, 26. [Epub ahead of print].
34. Karadag A.S., Tutal E., Ertugrul D.T., Akin K.O., Bilgili S.G. Serum holotranscobalamine, vitamin B12, folic acid and homocysteine levels in patients with vitiligo. Clin Exp Dermatol 2012, 37:62-64.
35. Huggins R.H., Janusz C.A., Schwartz R.A. Vitiligo: a sign of systemic disease. Indian J Dermatol Venereol Leprol 2006, 72:68-71.
36. Majumder P.A. Genetics and prevalence of vitiligo vulgaris. Vitiligo: A Monograph on the Basic and Clinical Science 2000, 18-20. Blackwell Science Ltd, Oxford. S.K. Hann, J.J. Nordlund (Eds.).
37. Ongenae K., Van Geel N., Naeyaert J.M. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003, 16:90-100.
38. Lee B.W., Schwartz R.A., Hercogová J., Valle Y., Lotti T.M. Vitiligo road map. Dermatol Ther 2012, 25(Suppl. 1):S44-S56.
39. Lotti T.M., Hercogová J., Schwartz R.A., et al. Treatments of vitiligo: what's new at the horizon. Dermatol Ther 2012, 25(Suppl. 1):S32-S40.
40. Valle Y., Lotti T.M., Hercogova J., Schwartz R.A., Korobko I.V. Multidisciplinary approach to R&D in vitiligo, a neglected skin disease. Dermatol Ther 2012, 25(Suppl. 1):S1-S9.
41. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.